Skip to main content
. Author manuscript; available in PMC: 2022 Mar 15.
Published in final edited form as: Nat Cancer. 2020 Jan 13;1(1):112–121. doi: 10.1038/s43018-019-0009-7

Fig. 6 |. Landscape of germline HRD across AA and EA patients in the pan-cancer and LuSC TCGA cohort.

Fig. 6 |

Prevalence of germline HRD in AAs and EAs, calculated using the total frequency of germline pathogenic variants in homologous recombination pathway genes in pan-cancer (left; n = 8,920 patients (AA = 919; EA = 8,001)) and LUSC (right; n = 382 patients (AA = 31; EA = 351)). Significance for the comparison of frequency of germline HRD was calculated via one-sided Fisher’s exact test. Exact P values are provided at the top of each plot.